Gamma Sensory Flicker for Parkinson's Disease Patients With Freezing of Gait
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Number of participants with Adverse events
研究概览
简要总结
This study aims to answer the question: to assess the safety, and tolerability of gamma light in Parkinson's disease (PD) patients with freezing of gait (FOG).
Parkinson's disease (PD) patients often experience a complex gait disorder known as Freezing of Gait (FOG). FOG is characterized by brief arrests of stepping when initiating gait, turning, and walking straight and patients describe it as their feet being "glued" to the floor. FOG in Parkinson's disease (PD) is a considerable public health burden worldwide. It is a poorly understood gait symptom that has potentially grave consequences as FOG is intermittent and unpredictable, a leading cause of falls with injury, and results in loss of independence. FOG is generally found to be associated with cognitive decline, particularly executive dysfunction which, in turn, has been associated with higher spinal fluid amyloid (Aβ42) levels in PD.
There is data linking amyloid to FOG. A previous study showed that the gamma light helped reduce some amyloid. The research team is studying if gamma light exposure for 1 hour daily is well tolerated. Also, does it have any effect on freezing of gait severity?
详细描述
This will be a sham-controlled study with one group receiving the sensory stimulation and the other receiving sham stimulation.
Exposure will be provided by wearing a pair of glasses and headphones. Both of these will be connected to a device that will provide light and sound during the daily 1-hour session.
Gamma light appeared in a previous study to have potential as a non-invasive, non-medication approach to reduce amyloid from the brain. This study will investigate if the link between amyloid and FOG can be changed and improve FOG.
Gamma is a short wavelength of light and/or sound between 25-140Hz. Previous research suggested that 40Hz can potentially activate cells in the brain to remove amyloid. Amyloid is a protein that forms in the spaces between nerve cells in the brain in diseases such as Alzheimer's and Parkinson's disease.
This study also has two optional parts. One option is to undergo two lumbar punctures at the baseline and Month 6 visits. The other option is to participate in a one-year extension of the study. Blood draws will be used to verify levodopa levels in the blood during both the ON and OFF Parkinson's disease medication states.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PD Diagnosis by UK Brain Bank Criteria
- •Hoehn & Yahr stage I-IV in the off-state
- •FOG noted in medical history
- •FOG confirmed visually by the examiner in the office
- •PD that is levodopa-treated and responsive
- •Able to manage 12 hours of "OFF" dopaminergic medication state
- •Age 50-80 years
- •Able to sign a consent document and willing to participate in all aspects of the study
排除标准
- •A diagnosis of atypical Parkinsonism, including vascular Parkinsonism
- •Prior treatment with medications that cause Parkinsonism
- •Stage V PD -unable to walk independently when OFF
- •Absence of levodopa response
- •Neurological or orthopedic disorders interfering with gait
- •Dementia precluding completing the study protocol, including those meeting criteria for dementia with Lewy bodies
- •Major depression based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria
- •Any medical problems that would preclude participation, including individuals with a history of migraines, tinnitus, or seizures, because sensory stimuli can potentially exacerbate these conditions.
- •Profound sensory loss as determined by the investigator.
研究组 & 干预措施
Flicker Exposure (Treatment Group)
Participants will be instructed to take home the stimulation equipment. Participants and their study partners (if applicable) will be trained on how to use the device before leaving the facility. Each device case also includes an instruction document. Participants and/or study partners (if applicable) will keep a manual log of daily operation, including the time of day used, whether the participant felt drowsy or, was able to complete the entire session, or if the participant was unable to complete the therapy that day. Finally, study staff will contact participants monthly every 2 weeks to ensure compliance, assess adverse events, and log concomitant medications.
干预措施: David Delight Plus Device (Device)
Control Group
Participants will receive sham stimulation. Participants and/or study partners (if applicable) will keep a manual log of daily operation, including the time of day used, whether the participant felt drowsy or, was able to complete the entire session, or if the participant was unable to complete the therapy that day. Finally, study staff will contact participants monthly every 2 weeks to ensure compliance, assess adverse events, and log concomitant medications.
干预措施: Sham Therapy (Other)
结局指标
主要结局
Number of participants with Adverse events
时间窗: up to 6 months
Participants will document the occurrence of any adverse events that occur during the flicker exposure to evaluate the safety and tolerability.
Number of participants compliant with the study procedures
时间窗: up to 6 months
Compliance will be measured by the number of participants who adhere to the study procedures (at-home usage, monitored by the device, and manual log of daily operation by the participants and their study partners).
次要结局
- Change in the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scale in participants with PD(Baseline and up to 6 months)
- Change in the freezing of gait severity in participants with PD.(Baseline and up to 6 months)
- Change in subjective changes in FOG.(Baseline and 6 months)
研究者
Stewart Factor
Principal Investigator
Emory University